1. Home
  2. PIM vs ACRS Comparison

PIM vs ACRS Comparison

Compare PIM & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PIM
  • ACRS
  • Stock Information
  • Founded
  • PIM 1988
  • ACRS 2012
  • Country
  • PIM United States
  • ACRS United States
  • Employees
  • PIM N/A
  • ACRS N/A
  • Industry
  • PIM Finance Companies
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PIM Finance
  • ACRS Health Care
  • Exchange
  • PIM Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • PIM 161.4M
  • ACRS 165.7M
  • IPO Year
  • PIM N/A
  • ACRS 2015
  • Fundamental
  • Price
  • PIM $3.31
  • ACRS $1.80
  • Analyst Decision
  • PIM
  • ACRS Strong Buy
  • Analyst Count
  • PIM 0
  • ACRS 9
  • Target Price
  • PIM N/A
  • ACRS $9.25
  • AVG Volume (30 Days)
  • PIM 57.5K
  • ACRS 1.4M
  • Earning Date
  • PIM 01-01-0001
  • ACRS 08-07-2025
  • Dividend Yield
  • PIM 8.28%
  • ACRS N/A
  • EPS Growth
  • PIM N/A
  • ACRS N/A
  • EPS
  • PIM 0.05
  • ACRS N/A
  • Revenue
  • PIM N/A
  • ACRS $16,789,000.00
  • Revenue This Year
  • PIM N/A
  • ACRS N/A
  • Revenue Next Year
  • PIM N/A
  • ACRS $8.11
  • P/E Ratio
  • PIM $63.80
  • ACRS N/A
  • Revenue Growth
  • PIM N/A
  • ACRS N/A
  • 52 Week Low
  • PIM $2.90
  • ACRS $1.05
  • 52 Week High
  • PIM $3.28
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • PIM 43.97
  • ACRS 62.45
  • Support Level
  • PIM $3.32
  • ACRS $1.75
  • Resistance Level
  • PIM $3.35
  • ACRS $1.92
  • Average True Range (ATR)
  • PIM 0.03
  • ACRS 0.09
  • MACD
  • PIM -0.00
  • ACRS 0.01
  • Stochastic Oscillator
  • PIM 12.50
  • ACRS 70.00

About PIM Putnam Master Intermediate Income Trust

Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: